Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Breast Neoplasms 1

Interventions

Cyclophosphamide 48fludarabine phosphate 32Peripheral Blood Stem Cell Transplantation 32Whole-Body Irradiation 26Etoposide 23Mycophenolic Acid 22Rituximab 20Filgrastim 18Doxorubicin 18Vincristine 16Cyclosporine 16Busulfan 16Tacrolimus 15Prednisone 15Methotrexate 13Melphalan 13Antilymphocyte Serum 12Cytarabine 11Radiotherapy 10Carboplatin 10Bortezomib 9romidepsin 8Ifosfamide 8Cord Blood Stem Cell Transplantation 8Methylprednisolone 7Lenalidomide 7Flow Cytometry 7Brentuximab Vedotin 7Sirolimus 6Everolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large-Cell, Anaplastic × parsaclisib × Clear all
NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
5 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡